• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

最近的美国甲状腺协会(ATA)指南是否能准确指导 MEN2A 患者预防性甲状腺切除术的时机?

Do the recent American Thyroid Association (ATA) Guidelines accurately guide the timing of prophylactic thyroidectomy in MEN2A?

机构信息

Department of Surgical Oncology, University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, USA.

出版信息

Surgery. 2010 Dec;148(6):1302-9; discussion 1309-10. doi: 10.1016/j.surg.2010.09.020.

DOI:10.1016/j.surg.2010.09.020
PMID:21134565
Abstract

BACKGROUND

In 2009, the American Thyroid Association (ATA) published consensus guidelines for timing of prophylactic thyroidectomy (PrThy) for treatment of hereditary medullary thyroid cancer (MTC). The aim of this study was to assess whether the clinical guidelines outlined in the ATA recommendations added to the specific mutation risk level could predict the presence of MTC on final pathology.

METHODS

A retrospective study was performed of patients undergoing PrThy. We evaluated mutation-based risk levels in combination with 2009 ATA guidelines for resection.

RESULTS

Overall, 54 patients underwent PrThy between 1972 and 2009. The median age at PrThy was 11.5 years (range, 2-68). Only 4 patients (8%) underwent PrThy prior to age 5 years. Most patients with MTC (16/22, 73%) had a level C mutation, and the youngest age of MTC in a level C mutation carrier was 5 years. The youngest age of MTC in level A or B carriers was 15 years. The single factor that predicted an overall decreased risk of MTC at the time of PrThy was meeting all ATA mutation-based postponement guidelines for surgical intervention (P = .04).

CONCLUSION

ATA guidelines that includes risk assessment of RET mutation are important in predicting the presence of MTC in patients who are candidates for prophylactic thyroidectomy and in determining the timing of operative resection.

摘要

背景

2009 年,美国甲状腺协会(ATA)发布了预防性甲状腺切除术(PrThy)治疗遗传性髓样甲状腺癌(MTC)时机的共识指南。本研究旨在评估 ATA 推荐中概述的临床指南是否结合特定的突变风险水平可以预测最终病理中 MTC 的存在。

方法

对行 PrThy 的患者进行回顾性研究。我们评估了基于突变的风险水平,并结合 2009 年 ATA 切除指南进行评估。

结果

总体而言,1972 年至 2009 年间有 54 例行 PrThy。PrThy 的中位年龄为 11.5 岁(范围,2-68 岁)。只有 4 名患者(8%)在 5 岁之前行 PrThy。大多数 MTC 患者(16/22,73%)存在 C 级突变,C 级突变携带者中 MTC 的最小年龄为 5 岁。A 级或 B 级携带者中 MTC 的最小年龄为 15 岁。总体上降低 PrThy 时 MTC 风险的唯一因素是符合 ATA 基于突变的所有手术干预推迟指南(P =.04)。

结论

包括 RET 突变风险评估的 ATA 指南对于预测预防性甲状腺切除术候选者中 MTC 的存在以及确定手术切除的时机非常重要。

相似文献

1
Do the recent American Thyroid Association (ATA) Guidelines accurately guide the timing of prophylactic thyroidectomy in MEN2A?最近的美国甲状腺协会(ATA)指南是否能准确指导 MEN2A 患者预防性甲状腺切除术的时机?
Surgery. 2010 Dec;148(6):1302-9; discussion 1309-10. doi: 10.1016/j.surg.2010.09.020.
2
Early, Prophylactic Thyroidectomy in Hereditary Medullary Thyroid Carcinoma: A 26-year Monoinstitutional Experience.遗传性甲状腺髓样癌的早期预防性甲状腺切除术:一项长达26年的单机构经验
Am J Clin Oncol. 2015 Oct;38(5):508-13. doi: 10.1097/COC.0b013e3182a78fec.
3
Ultrasonography should not guide the timing of thyroidectomy in pediatric patients diagnosed with multiple endocrine neoplasia syndrome 2A through genetic screening.超声检查不应用于指导经基因筛查诊断为多发性内分泌肿瘤综合征 2A 的小儿患者的甲状腺切除术时机。
Ann Surg Oncol. 2013 Jan;20(1):53-9. doi: 10.1245/s10434-012-2589-7. Epub 2012 Aug 14.
4
Therapeutic Effectiveness of Screening for Multiple Endocrine Neoplasia Type 2A.多内分泌腺肿瘤 2A 筛查的治疗效果。
J Clin Endocrinol Metab. 2015 Jul;100(7):2539-45. doi: 10.1210/jc.2015-1689. Epub 2015 May 6.
5
p.Val804Met, the Most Frequent Pathogenic Mutation in RET, Confers a Very Low Lifetime Risk of Medullary Thyroid Cancer.p.Val804Met 是 RET 中最常见的致病性突变,其导致终身患甲状腺髓样癌的风险非常低。
J Clin Endocrinol Metab. 2018 Nov 1;103(11):4275-4282. doi: 10.1210/jc.2017-02529.
6
When is prophylactic thyroidectomy indicated for patients with the RET codon 609 mutation?对于携带RET密码子609突变的患者,何时需要进行预防性甲状腺切除术?
Ann Surg Oncol. 2009 Aug;16(8):2237-44. doi: 10.1245/s10434-009-0524-3. Epub 2009 May 27.
7
Hereditary Medullary Thyroid Cancer Genotype-Phenotype Correlation.遗传性甲状腺髓样癌的基因型-表型相关性
Recent Results Cancer Res. 2015;204:139-56. doi: 10.1007/978-3-319-22542-5_6.
8
Prophylactic thyroidectomy for MEN 2-related medullary thyroid carcinoma based on predictive testing for RET proto-oncogene mutation and basal serum calcitonin in China.基于中国 RET 原癌基因突变和基础降钙素检测对 MEN2 相关甲状腺髓样癌的预防性甲状腺切除术。
Eur J Surg Oncol. 2013 Sep;39(9):1007-12. doi: 10.1016/j.ejso.2013.06.015. Epub 2013 Jul 9.
9
Prophylactic thyroidectomies in MEN2 syndrome: Management and outcomes.MEN2综合征中的预防性甲状腺切除术:管理与结果
J Pediatr Surg. 2018 Feb;53(2):283-285. doi: 10.1016/j.jpedsurg.2017.11.015. Epub 2017 Nov 13.
10
Present status of prophylactic thyroidectomy in pediatric multiple endocrine neoplasia 2: a nationwide survey in Japan 1997-2017.儿童多发性内分泌腺瘤病2型预防性甲状腺切除术的现状:1997 - 2017年日本全国性调查
J Pediatr Endocrinol Metab. 2019 Jun 26;32(6):585-595. doi: 10.1515/jpem-2018-0444.

引用本文的文献

1
Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey.土耳其遗传性甲状腺髓样癌中RET突变的分布及治疗方法评估
J Clin Res Pediatr Endocrinol. 2016 Mar 5;8(1):13-20. doi: 10.4274/jcrpe.2219. Epub 2015 Dec 18.
2
Integrated DNA-based/biochemical screening for early diagnosis of multiple endocrine neoplasia type 2A (MEN2A).基于DNA/生化综合筛查用于2A型多发性内分泌腺瘤病(MEN2A)的早期诊断
J Biomed Res. 2013 Mar;27(2):145-50. doi: 10.7555/JBR.27.20120121. Epub 2013 Feb 20.
3
RET gene abnormalities and thyroid disease: who should be screened and when.
RET基因异常与甲状腺疾病:谁应接受筛查以及何时筛查。
J Clin Res Pediatr Endocrinol. 2013;5 Suppl 1(Suppl 1):70-8. doi: 10.4274/Jcrpe.870.
4
Ultrasonography should not guide the timing of thyroidectomy in pediatric patients diagnosed with multiple endocrine neoplasia syndrome 2A through genetic screening.超声检查不应用于指导经基因筛查诊断为多发性内分泌肿瘤综合征 2A 的小儿患者的甲状腺切除术时机。
Ann Surg Oncol. 2013 Jan;20(1):53-9. doi: 10.1245/s10434-012-2589-7. Epub 2012 Aug 14.
5
Evolving paradigms for successful molecular imaging of medullary thyroid carcinoma.甲状腺髓样癌成功分子成像的不断演变的范式。
Eur J Nucl Med Mol Imaging. 2012 Apr;39(4):563-8. doi: 10.1007/s00259-011-2035-2.
6
Hereditary medullary thyroid carcinoma: the management dilemma.遗传性髓样甲状腺癌:管理困境。
Fam Cancer. 2012 Jun;11(2):157-65. doi: 10.1007/s10689-011-9501-7.
7
Management of medullary thyroid carcinoma and MEN2 syndromes in childhood.儿童时期的甲状腺髓样癌和 MEN2 综合征的管理。
Nat Rev Endocrinol. 2011 Aug 23;7(10):596-607. doi: 10.1038/nrendo.2011.139.